Humanized Mouse Model of Thrombosis Is Predictive of the Clinical Efficacy of Antiplatelet Agents
暂无分享,去创建一个
G. Dangas | T. Diacovo | J. Bussel | Jianchun Chen | L. Rabbani | J. Magallon | Jing Yang
[1] A. Michelson. Antiplatelet therapies for the treatment of cardiovascular disease , 2010, Nature Reviews Drug Discovery.
[2] P. Billings,et al. The structure and function of platelet integrins , 2009, Journal of thrombosis and haemostasis : JTH.
[3] M. Lordkipanidzé,et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. , 2008, European heart journal.
[4] Barry S Coller,et al. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. , 2008, Blood.
[5] B. Furie,et al. Mechanisms of thrombus formation. , 2008, The New England journal of medicine.
[6] J. Hirsh,et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[7] H. Deckmyn,et al. Signalling pathways; , 2022 .
[8] M. Kahn,et al. Platelet integrins and immunoreceptors , 2007, Immunological reviews.
[9] Justin T. Newcomer,et al. Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study , 2007, Circulation.
[10] D. Wagner,et al. Platelet adhesion receptors and their ligands in mouse models of thrombosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[11] Debbie Singh,et al. Clopidogrel for up to one year after PCI is cost-effective for people with acute coronary syndromes. , 2006, Evidence-based cardiovascular medicine.
[12] C. Napoli,et al. In vivo veritas: Thrombosis mechanisms in animal models , 2006, Scandinavian journal of clinical and laboratory investigation.
[13] C. Abrams. Intracellular signaling in platelets , 2005, Current opinion in hematology.
[14] J. Takagi,et al. Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[15] E. Topol,et al. Integrin alphaIIbbeta3 and its antagonism. , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[16] K. Schrör,et al. Comparative Pharmacology of GP IIb/IIIa Antagonists , 2003, Journal of Thrombosis and Thrombolysis.
[17] S. Yusuf,et al. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. , 2003, Journal of the American College of Cardiology.
[18] Scott L. Diamond,et al. Selectin-Like Kinetics and Biomechanics Promote Rapid Platelet Adhesion in Flow: The GPIbα-vWF Tether Bond , 2002 .
[19] A. Matzdorff,et al. Comparison of GP IIB/IIIA Inhibitors and Their Activity as Measured by Aggregometry, Flow Cytometry, Single Platelet Counting, and the Rapid Platelet Function Analyzer , 2001, Journal of Thrombosis and Thrombolysis.
[20] M. Gawaz,et al. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists. , 2001, Thrombosis research.
[21] M. Seyfarth,et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement , 2001, Heart.
[22] B. Nieswandt,et al. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. , 2000, Blood.
[23] S. Coughlin,et al. Thrombin signalling and protease-activated receptors , 2000, Nature.
[24] A. Gagnon,et al. Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. , 2000, Journal of pharmacological and toxicological methods.
[25] S. Mousa,et al. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[26] L. Jennings,et al. Interspecies Comparison of Platelet Aggregation, LIBS Expression and Clot Retraction: Observed Differences in GPIIb-IIIa Functional Activity , 1995, Thrombosis and Haemostasis.
[27] J. Sixma,et al. Increased platelet deposition on atherosclerotic coronary arteries. , 1994, The Journal of clinical investigation.
[28] A. Schreiber,et al. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli. , 1991, Biochemistry.
[29] D. Baruch,et al. Production in Escherichia coli of a biologically active subfragment of von Willebrand factor corresponding to the platelet glycoprotein Ib, collagen and heparin binding domains. , 1989, Biochemical and biophysical research communications.
[30] H. Gold,et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. , 1988, The Journal of clinical investigation.
[31] H. Gold,et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. , 1988, Circulation.
[32] J. Mustard,et al. Effects of the cell adhesion peptide, Arg-Gly-Asp-Ser, on responses of washed platelets from humans, rabbits, and rats. , 1987, Blood.
[33] J. Sixma,et al. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII–Von Willebrand factor bound to the subendothelium , 1979, Nature.
[34] R. Liddington,et al. Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies , 2008, Nature Biotechnology.
[35] C. Sebastiano,et al. Hermansky-pudlak syndrome: report of a case and review of the literature. , 2008, International journal of clinical and experimental pathology.
[36] Z. Ruggeri,et al. Adhesion Mechanisms in Platelet Function , 2007 .
[37] B. Nieswandt,et al. Activation of Platelet Function Through G Protein–Coupled Receptors , 2006, Circulation research.
[38] A. Palucka,et al. Humanized mice: are we there yet? , 2005 .
[39] T. Springer,et al. Amino acid residues in the alpha IIb subunit that are critical for ligand binding to integrin alpha IIbbeta 3 are clustered in the beta-propeller model. , 2001, The Journal of biological chemistry.
[40] D. Heitjan,et al. Mixed-effects models in psychophysiology. , 2000, Psychophysiology.